Sanofi-Aventis Recherche & Developpement — Sponsor Intelligence | 116 EU Trials

Filter these 116 trials by condition, phase, country and more.

Open in Search →

116 Registered trials

45 Recruiting

66 Completed trials

25 Countries active

78 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 43 Phase II/III: 4 Phase II: 41 Phase I/II: 6 Phase IV: 2 Phase I: 6 Phase I (Other): 8 Phase I (FiH): 4 Other: 1 Other: 1

Oversight events:

5 temporary halts 3 unexpected events 1 corrective measure across 6 trials

View oversight register →

100%

66 of 66 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Dermatitis atopic 9 Chronic obstructive pulmonary disease 7 Multiple sclerosis 6 Plasma cell myeloma refractory 6 Asthma 6 Chronic rhinosinusitis with nasal polyps 5 Colitis ulcerative 5 Crohn´s disease 4 Plasma cell myeloma 3 Autoimmune haemolytic anaemia 2 Clinical trial participant 2 Neurodermatitis 2

Top IMPs

ISATUXIMAB 10 AMLITELIMAB 9 DEXAMETHASONE 9 ITEPEKIMAB 9 FREXALIMAB 6 LUNSEKIMIG 6 DUPILUMAB 5 RILIPRUBART 5 RILZABRUTINIB 5 DEXAMETHASONE SODIUM PHOSPHATE PH. EUR. 4 DUVAKITUG 4 BALINATUNFIB 3

All trials — page 4

116 total

Efficacy and safety of Frexalimab (SAR441344) in the treatment of Systemic Lupus Erythematosus Ended

2023-508654-26-00 Phase II 4 countries FREXALIMAB
Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia Ended

2023-509441-13-00 Phase II 3 countries RILZABRUTINIB
Proof-of-concept study for SAR441344 (frexalimab) in relapsing multiple sclerosis. Ended

2024-513527-17-00 Phase II 5 countries FREXALIMAB
Isatuximab in combination with belantamab mafodotin and dexamethasone in RRMM. Ended

2024-514989-40-00 Phase I/II 3 countries BELANTAMAB MAFODOTIN; DEXAMETHASONE; ISATUXIMAB
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended

2023-507419-37-00 Phase III 11 countries DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; DEXAMETHASONE SODIUM PHOSPHATE PH…
A study to investigate the clinical benefit of isatuximab in combination with bortezomib, lenalidomide and dexamethasone in adults with newl… Ended

2024-514417-34-00 Phase III 11 countries BORTEZOMIB; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; DEXAMETHASONE SODIUM …
A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B Ended

2024-513500-34-00 Phase II 1 country LENTIVIRAL VECTOR DERIVED FROM THE EQUINE INFECTIOUS ANAEMIA VIRUS CONTAINING TH…
Phase I/II Follow-up Study of SAR422459 in Patients with Stargardt’s Macular Degeneration Ended

2024-513501-31-00 Phase II 1 country LENTIVIRAL VECTOR CONTAINING THE HUMAN ABCA4 GENE
Phase 1 study on SAR443122 bioavailability and food effect in healthy adults Ended

2025-521073-13-00 1 country
A study to investigate how different tablet types of balinatunfib and food will influence the absorption of balinatunfib in blood in healthy… Ended

2024-519860-41-00 Phase I (Other) 1 country
A study to investigate the efficacy and safety of subcutaneous lunsekimig (SAR443765) compared with placebo in adult participants with moder… Ended

2024-511549-20-00 Phase II 2 countries LUNSEKIMIG
A study to investigate the bioavailability of the SAR444656 test formulation and the food effect on the SAR444656 test formulation in health… Ended

2024-515621-28-00 Phase I (Other) 1 country
A proof-of-concept study of lunsekimig compared with placebo in adults with chronic rhinosinusitis with nasal polyps Ended

2024-511261-11-00 Phase II 3 countries LUNSEKIMIG
An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates Ended

2024-513495-17-00 Phase I (Other) 2 countries
A first-in-human study to investigate safety and tolerability of SAR446959 in participants with osteoarthritis of the knee Ended

2024-514015-96-00 Phase I 1 country
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe … Ended

2024-511225-64-00 Phase II 8 countries AMLITELIMAB
A study to investigate immune challenge induced skin reactions with SAR445399, canakinumab and spesolimab compared with placebo, in healthy … Ended

2024-511241-19-00 Phase I (Other) 1 country
A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop… Ended

2023-506558-20-00 Phase III 6 countries AMLITELIMAB
Effect of SAR445611 on inflammatory responses following LPS challenge study in healthy participants Ended

2024-511618-19-00 Phase I (Other) 1 country
A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr… Ended

2023-508663-70-00 Phase II 9 countries ITEPEKIMAB
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended

2022-501196-41-00 Phase III 4 countries AMLITELIMAB
Safety and tolerability of single and multiple ascending doses of lunsekimig (SAR443765) in healthy participants Ended

2023-509316-28-00 Phase I (Other) 1 country
A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended

2023-503910-60-00 Phase II 6 countries SAR441566
A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by t… Ended

2023-508030-33-00 1 country

Showing 73–96 of 116 trials

← All sponsors A–Z